Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma

被引：90

作者：

Benetatos, Leonidas ^{[1
]}

Dasoula, Aggeliki ^{[2
]}

Hatzimichael, Eleftheria ^{[1
]}

Georgiou, Ioannis ^{[3
]}

Syrrou, Maria ^{[2
]}

Bourantas, Konstantinos L. ^{[1
]}

机构：

[1] Univ Hosp Ioannina, Dept Hematol, Ioannina, Greece

[2] Univ Hosp Ioannina, Dept Gen Biol, Ioannina, Greece

[3] Univ Hosp Ioannina, Dept Genet, Ioannina, Greece

来源：

CLINICAL LYMPHOMA & MYELOMA | 2008年 / 8卷 / 03期

关键词：

bisulphite DNA modification; epigenetic gene modification; methylation; polymerase chain reaction;

D O I：

10.3816/CLM.2008.n.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Methylation represents the most studied epigenetic modification and results in the silencing of genes involved in various processes such as differentiation and cell-cycle regulation. MEG3 represents an imprinted gene maternally expressed in humans that encodes a nontranslated product. In this survey, we studied the methylation status of the specific gene in multiple myeloma (MM). Patients and Methods: Twenty-one patients with MM (17 with immunoglobulin [Ig] G, 3 with IgA, and 1 with IgM) were evaluated using methylation-specific polymerase chain reaction (after DNA bisulphite modification). Results: Promoter hypermethylation was observed in 12 (57.14%) bone marrow samples and in 9 of 14 (64.28%) available peripheral blood samples. A correlation with disease stage was also observed and also with the disease subtype (IgG, 64.7%; IgA, 0; IgM, 100%). Conclusion: We conclude that promoter hypermethylation of the differentially methylated region of the MEG3 imprinted gene is observed in patients with MM.

引用

页码：171 / 175

页数：5

共 28 条

[1] Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia:: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour
Astuti, D
Latif, F
Wagner, K
Gentle, D
Cooper, WN
Catchpoole, D
Grundy, R
Ferguson-Smith, AC
Maher, ER
[J]. BRITISH JOURNAL OF CANCER, 2005, 92 (08) : 1574 - 1580
[2] dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats
Baladrón, V
Ruiz-Hidalgo, MJ
Nueda, ML
Díaz-Guerra, MJM
García-Ramírez, JJ
Bonvini, E
Gubina, E
Laborda, J
[J]. EXPERIMENTAL CELL RESEARCH, 2005, 303 (02) : 343 - 359
[3] The EGF-like homeotic protein dlk affects cell growth and interacts with growth-modulating molecules in the yeast two-hybrid system
Baladrón, V
Ruiz-Hidalgo, MJ
Bonvini, E
Gubina, E
Notario, V
Laborda, J
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 291 (02) : 193 - 204
[4] Methylation profiling in multiple myeloma
Chim, CS
Kwong, YL
Fung, TK
Liang, R
[J]. LEUKEMIA RESEARCH, 2004, 28 (04) : 379 - 385
[5] Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines
Drucker, L
Tohami, T
Tartakover-Matalon, S
Zismanov, V
Shapiro, H
Radnay, J
Lishner, M
[J]. CARCINOGENESIS, 2006, 27 (02) : 197 - 204
[6] Imprinting, expression, and localisation of DLK1 in Wilms tumours
Fukuzawa, R
Heathcott, RW
Morison, IM
Reeve, AE
[J]. JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (02) : 145 - 150
[7] Tumor suppressor p16 methylation in multiple myeloma:: biological and clinical implications
Gonzalez-Paz, Natalia
Chng, Wee J.
McClure, Rebecca F.
Blood, Emily
Oken, Martin M.
Van Ness, Brian
James, C. David
Kurtin, Paul J.
Henderson, Kimberly
Ahmann, Gregory J.
Gertz, Morie
Lacy, Martha
Dispenzieri, Angela
Greipp, Philip R.
Fonseca, Rafael
[J]. BLOOD, 2007, 109 (03) : 1228 - 1232
[8] GREIPP RR, 2003, HAEMATOL J S1, V4, pS43
[9] Guillerm GL, 2003, HAEMATOLOGICA, V88, P476
[10] Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
Herman, JG
Baylin, SB
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) : 2042 - 2054

← 1 2 3 →